cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access
Rhea-AI Summary
cbdMD (NYSE American: YCBD) announced its support for the bipartisan Lawful Hemp Protection Act introduced on July 21, 2026 by Reps. Andy Barr and Angie Craig. The bill seeks a long-term federal framework for hemp-derived products and would repeal a November 12, 2026 narrowing of the federal hemp definition under Section 781 of the FY 2026 appropriations law.
The proposed act would place hemp-derived products under FDA oversight, require third-party testing and accurate labeling, set 21-and-over age limits, mandate domestic sourcing, and restrict synthetic intoxicating cannabinoids. cbdMD also backs the Administration and Office of Management and Budget’s calls to revise the hemp definition through budget legislation.
Positive
- None.
Negative
- None.
News Market Reaction – YCBD
In the Jul 24 session, YCBD declined 6.65%, reflecting a notable negative market reaction. Argus tracked a trough of -5.5% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Distribution partnership | Positive | -2.4% | Oasis distribution agreement expanded availability across South Carolina liquor stores. |
| Jul 09 | Conservation partnership | Positive | +8.0% | Bluebird Botanicals partnered with Denver Audubon and committed 1% of profits. |
| Jul 07 | GRAS determination | Positive | +3.6% | Independent toxicologist panel supported daily intake of up to 200 mg CBD. |
| Jul 01 | Product launch | Positive | +1.0% | Oasis Mixer launched with initial distributor demand and availability in multiple states. |
| Jun 25 | Hemp policy support | Positive | +6.3% | YCBD welcomed federal support for fair treatment of hemp-derived products. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
YCBD aligned with positive news reactions in 4 of 5 recent events, while one partnership announcement diverged negatively.
Key Terms
full-spectrum cbd technical
fda oversight regulatory
third-party testing regulatory
interstate commerce regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company backs the Barr-Craig framework and the administration's call to fix the federal hemp definition before the November deadline
The legislation comes at a pivotal time for the
The bipartisan sponsorship reflects a growing consensus that responsible regulation, rather than prohibition, is the appropriate path forward for the hemp industry. The bill would establish FDA oversight for hemp-derived products, with mandatory third-party testing, transparent labeling, a 21-and-over age requirement, and domestic sourcing, while targeting the synthetic intoxicants that have drawn scrutiny to the category.
Specifically, cbdMD supports a federal framework that:
- Protects access to responsibly manufactured full-spectrum CBD
- Requires independent testing and accurate labeling
- Establishes clear manufacturing and marketing standards, including limits on youth-focused marketing
- Prevents youth access through a 21-and-over requirement
- Restricts synthetic and artificially modified cannabinoids
- Preserves lawful interstate commerce for compliant products
cbdMD also welcomed the Office of Management and Budget's recent call for Congress to update the hemp definition through the funding process, which the company believes could provide relief before the November deadline if enacted.
As one of the nation's longest-standing hemp-derived CBD companies, cbdMD believes a consistent federal regulatory framework would significantly benefit consumers and responsible businesses alike by improving consumer confidence, strengthening safety standards, and providing greater certainty for manufacturers and retailers.
"Reps. Barr and Craig have demonstrated bipartisan leadership by advancing a practical regulatory framework for hemp-derived products," said Ronan Kennedy, Chief Executive Officer of cbdMD. "Responsible companies have long supported clear federal standards that protect consumers, promote product quality, and distinguish compliant hemp products from illicit synthetic intoxicants. We encourage Congress to act before the November implementation deadline."
About cbdMD, Inc.
cbdMD, Inc. (NYSE American: YCBD) is a Charlotte, North Carolina-based hemp-derived wellness company committed to safe, high-quality, science-backed products. Its family of brands includes cbdMD, cbdMD Science, Bluebird Botanicals, Paw CBD, Oasis, and ATRx Labs. For more information, visit cbdMD.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Statements regarding pending legislation, regulatory developments, and their potential impact on the company are based on current expectations and are subject to risks and uncertainties, including the outcome of the legislative and regulatory processes described above and risks disclosed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Actual results may differ materially. The company undertakes no obligation to update any forward-looking statement except as required by law.
Contacts
cbdMD, Inc.
Ronan Kennedy
Chief Executive Officer and Chief Financial Officer
IR@cbdmd.com
(704) 445-3064
View original content to download multimedia:https://www.prnewswire.com/news-releases/cbdmd-supports-the-bipartisan-lawful-hemp-protection-act-to-protect-consumers-and-full-spectrum-cbd-access-302834314.html
SOURCE cbdMD, Inc.